Progress with regenerative medicine is supporting the development of a new type of asthma treatment that has the potential to reduce asthma attacks and repair lung damage.
In this article:
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.
GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.
A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »